High concentration anti-C5 antibody formulations
The present disclosure relates to stable aqueous solutions comprising a high concentration of an anti-05 antibody (e.g., ravulizumab) and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), using the solutions. Also featured were therapeutic kits containing one or more of the solutions and a means for administering the solutions to a patient in need such a treatment.
1. A stable aqueous solution comprising:
(a) an anti-C5 antibody at a concentration of about 70 mg/mL, wherein the anti-C5 antibody comprises a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:19, a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:18, a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:3, a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:4, a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:5, and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:6;
(b) about 50 mM Phosphate Buffer;
(c) about 5% sucrose; and
(d) about 25 mM Arginine.
2. The stable aqueous solution of claim 1 , further comprising a surfactant.
3. The stable aqueous solution of claim 2 , wherein the surfactant is about 0.05% Polysorbate 80.
4. The stable aqueous solution of claim 1 , wherein the anti-C5 antibody comprises:
(a) a variant human Fc constant region that binds to human neonatal Fc receptor (FcRn), wherein the variant human Fc CH3 constant region comprises Met-429-Leu and
Asn-435-Ser substitutions at residues corresponding to methionine 428 and asparagine 434 of a native human IgG Fc constant region, each in EU numbering;
(b) a heavy chain variable region depicted in SEQ ID NO:12 and a light chain variable region depicted in SEQ ID NO:8;
(c) a heavy chain constant region depicted in SEQ ID NO:13; and/or
(d) a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO: 14 and a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO: 11.
5. The stable aqueous solution of claim 1 , wherein the anti-C5 antibody is ALXN1210 (ravulizumab).
6. The stable aqueous solution of claim 1 , wherein the pH of the solution is between 7.2 and 7.6.
7. The stable aqueous solution of claim 1 , wherein the pH of the solution is 7.4.
8. The stable aqueous solution of any one of claim 1 , wherein:
(a) the solution is sterile
(b) the anti-C5 antibody remains at least 97% monomeric during storage at 2° C. to 8° C. for at least six months or at least one year as determined by SEC-HPLC;
(c) less than 3%, less than 2% or less than 1% of the anti-CS antibody in the solution is aggregated as determined by SEC-HPLC; and/or
(d) during storage at 2° C. to 8° C. for at least six months the anti-CS antibody retains: at least 90% of its CS-binding activity, as compared to the anti-CS antibody prior to storage; and/or at least 95% of its ability to inhibit hemolysis, as compared to the anti-CS antibody prior to storage.
9. The stable aqueous solution of claim 1 , wherein the solution is suitable for subcutaneous administration.
10. The stable aqueous solution of claim 1 , wherein the solution is in a cartridge, prefilled syringe or disposable pen.
11. A therapeutic kit comprising: (i) the stable aqueous solution according to claim 1 and (ii) means for delivery of the stable aqueous solution to a human.
12. The therapeutic kit of claim 11 , wherein the means is a device.
13. The therapeutic kit of claim 12 , wherein the device is a syringe, a prefilled syringe, an auto-injector either disposable or reusable, a pen injector, a patch injector, a wearable injector, an ambulatory syringe infusion pump with subcutaneous infusion set, preferably an ambulatory syringe infusion pump with subcutaneous infusion set.